Anti-Interleukin-6 Receptor Antibody Therapy-Induced Retinopathy in a Patient with Rheumatoid Arthritis
Tocilizumab, a humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody, is beneficial for treating autoimmune conditions such as rheumatoid arthritis (RA). The most common adverse event is upper respiratory tract infection; ocular side effects are rare. We describe a case of skin ulce...
Saved in:
Main Authors: | Asumi Tada, Noriyasu Hashida, Toshio Tanaka, Kohji Nishida |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2012-01-01
|
Series: | Case Reports in Rheumatology |
Online Access: | http://dx.doi.org/10.1155/2012/270315 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Serum levels of interleukin-6 type cytokines and soluble interleukin-6 receptor in patients with rheumatoid arthritis
by: T. Robak, et al.
Published: (1998-01-01) -
Three Cases of Previous Smokers with Rheumatoid Arthritis Who Did Not Respond to Tumor Necrosis Factor Inhibitors Were Treated Successfully with an Anti-Interleukin-6 Receptor Antibody
by: Yasuo Iwata
Published: (2015-01-01) -
T-Cell Subsets in Rheumatoid Arthritis Patients on Long-Term Anti-TNF or IL-6 Receptor Blocker Therapy
by: Sonja Dulic, et al.
Published: (2017-01-01) -
Use of Anti-Interleukin-6 Receptor Monoclonal Antibody in Drug-Induced Acute Respiratory Distress Syndrome
by: Alessandra Petrillo, et al.
Published: (2020-01-01) -
Anti-Cyclic Citrullinated Peptide Antibodies and Severity of Interstitial Lung Disease in Women with Rheumatoid Arthritis
by: Alberto Daniel Rocha-Muñoz, et al.
Published: (2015-01-01)